New advances in genitourinary cancer: evidence gathered in 2014

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Metastasis Review

• Publication date

  2015-07-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10555-015-9577-xPMID 26227584
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)

  2016cited by this paper
• Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

  2015cited by this paper
• Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

  2015cited by this paper
• Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

  2015cited by this paper
• Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

  2015cited by this paper
• Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

  2015cited by this paper
• Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

  2015cited by this paper
• Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

  2015cited by this paper
• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

  2015cited by this paper
• Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.

  2015cited by this paper
• Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476).

  2015cited by this paper
• Beyond immune checkpoint blockade: New approaches to targeting host–tumor interactions in prostate cancer: Report from the 2014 Coffey–Holden prostate cancer Academy meeting

  2015cited by this paper
• Maintaining and reprogramming genomic androgen receptor activity in prostate cancer

  2014cited by this paper
• Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 Trial).

  2014cited by this paper
• Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

  2014cited by this paper
• DHH is an independent prognosticator of oncologic outcome of clear cell renal cell carcinoma.

  2014cited by this paper
• Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

  2014cited by this paper
• EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

  2014cited by this paper
• Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

  2014cited by this paper
• Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.

  2014cited by this paper
• Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse

  2014cited by this paper
• Targeting Poly(ADP-Ribose) Polymerase and the c-Myb–Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer

  2014cited by this paper
• Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer

  2014cited by this paper
• The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

  2014cited by this paper
• Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer

  2014cited by this paper
• Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

  2014cited by this paper
• PD-L1 is highly expressed in Enzalutamide resistant prostate cancer

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer

  2014cited by this paper
• Tumor clone dynamics in lethal prostate cancer

  2014cited by this paper
• The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response

  2014cited by this paper
• The use of breast MRI in early-stage breast cancer: Findings after implementation of an institutional protocol at a county hospital.

  2014cited by this paper
• Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma

  2014cited by this paper
• Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

  2014cited by this paper
• Optimal management of clinical stage I nonseminoma: new data for patients to consider.

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• 809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

  2014cited by this paper
• Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

  2014cited by this paper
• Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

  2014cited by this paper
• Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.

  2014cited by this paper
• Abstract LB-44: Persistent androgen ablation promotes enhanced neuroendocrine features in Pten-deficient prostate cancer

  2014cited by this paper
• Abstract 456: ERG regulation of intracrine androgen production and castration-resistant prostate cancer progression

  2014cited by this paper
• Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC).

  2014cited by this paper
• Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial)

  2014cited by this paper
• LBA20ANTITUMOUR ACTIVITY OF THE PARP INHIBITOR OLAPARIB IN UNSELECTED SPORADIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN THE TOPARP TRIAL

  2014cited by this paper
• Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.

  2014cited by this paper
• Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC).

  2014cited by this paper
• Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial.

  2014cited by this paper
• Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.

  2014cited by this paper
• Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).

  2014cited by this paper
• A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti–PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors.

  2014cited by this paper
• Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors.

  2014cited by this paper
• A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.

  2014cited by this paper
• Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

  2014cited by this paper
• Phase II trial of pazopanib and weekly paclitaxel in metastatic urothelial cancer (UC).

  2014cited by this paper
• A phase II study of cabazitaxel in patients with urothelial carcinoma who have disease progression following platinum-based chemotherapy.

  2014cited by this paper
• Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib.

  2014cited by this paper
• SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

  2014cited by this paper
• Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.

  2014cited by this paper
• Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.

  2014cited by this paper
• Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.

  2014cited by this paper
• First-in-human phase 1 study of the novel indoleamine-2,3-dioxygenase (IDO) inhibitor NLG-919.

  2014cited by this paper
• Molecular basis of giant cells in tuberous sclerosis complex.

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014cited by this paper
• Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

  2014cited by this paper
• Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

  2014cited by this paper
• 755OA RANDOMIZED PHASE 3 STUDY COMPARING FIRST-LINE DOCETAXEL/PREDNISONE (DP) TO DP PLUS CUSTIRSEN IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).

  2014cited by this paper
• 1049OSAFETY AND EFFICACY OF MPDL3280A (ANTI-PDL1) IN COMBINATION WITH BEVACIZUMAB (BEV) AND/OR CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.

  2014cited by this paper
• 1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

  2014cited by this paper
• The somatic genomic landscape of chromophobe renal cell carcinoma.

  2014cited by this paper
• Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

  2014cited by this paper
• Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.

  2014cited by this paper
• Comprehensive molecular characterization of urothelial bladder carcinoma

  2014cited by this paper
• Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer

  2014cited by this paper
• High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).

  2014cited by this paper
• A phase II study of trebananib (AMG 386) and abiraterone in metastatic castration resistant prostate cancer.

  2014cited by this paper
• 812PDMATURE SURVIVAL (OS) DATA OF A RANDOMISED INTERNATIONAL PHASE II TRIAL (JASINT1): VINFLUNINE (VFL)-GEMCITABINE (GEM) VS. VFL-CBDCA IN CDDP-UNFIT PATIENTS (PTS) WITH ADVANCED UROTHELIAL CARCINOMA (UC).

  2014cited by this paper
• Molecular genetics of clear-cell renal cell carcinoma.

  2014cited by this paper
• HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A

  2014cited by this paper
• Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)

  2014cited by this paper
• Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.

  2014cited by this paper
• The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression

  2014cited by this paper
• Spatial and temporal cancer evolution: causes and consequences of tumour diversity.

  2014cited by this paper
• RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma

  2014cited by this paper
• Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma

  2014cited by this paper
• Immunotherapy for prostate cancer: recent developments and future challenges

  2014cited by this paper
• Antiangiogenic therapies: going beyond their limits.

  2014cited by this paper
• Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts

  2014cited by this paper
• Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.

  2014cited by this paper
• Organoid cultures derived from patients with advanced prostate cancer.

  2014cited by this paper
• The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer

  2014cited by this paper
• Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers

  2014cited by this paper
• Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.

  2014cited by this paper
• Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.

  2014cited by this paper
• Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.

  2014cited by this paper
• Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

  2014cited by this paper
• Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

  2014cited by this paper
• Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

  2014cited by this paper

• Identification of Molecular Subgroups of Muscle-Invasive Urothelial Bladder Cancer and Their Impact on Treatment Outcome

  2024cites this paper
• The effect of mechanical force in genitourinary malignancies

  2021cites this paper
• lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System

  2020cites this paper
• Zonula occludens-1 associated nucleic acid binding protein plays an invasion-promoting role in bladder cancer.

  2019cites this paper
• Current Concepts in the Management of Muscle Invasive Bladder Cancer

  2017cites this paper